Cite
HARVARD Citation
Pavord, I. et al. (n.d.). S78 Dupilumab reduces risk of severe exacerbations and improves FEV1 regardless of baseline disease severity in patients with uncontrolled, moderate-to-severe asthma: data from the phase 3 LIBERTY ASTHMA QUEST study. Thorax. p. A48. [Online].